URINE METABOLITES CHARACTERIZE THE INFLAMMATORY BOWEL DISEASE

MARIA EMILIA CUENCAS BARRIENTOS; LEONELLA TANTUCCI; DAFNE CABRERA; MARINA LAURA FERNANDEZ; ADRIANA FOCHESATO; ANDREA DELGADO; CORREA SILVIA; BALDERRAMO, DOMINGO; ROMAGNOLI, PABLO ALBERTO

Santiago

Taller; Inflammation, Cancer and Intestinal Mucosal Immunology (ICIMI); 2023

IUIS-SMI-ALAI-LAMIG-ASOCHIN

Inflammatory Bowel Disease (IBD), which comprises Crohn's Disease (CD) and Ulcerative Colitis (UC), is a disorder in which complex interactions between genetic, environmental, and microbial factors trigger alterations in the immune responses of the intestinal mucosa that result in chronic intestinal inflammation. On the other hand, an individual's metabolic profile is the result of a combination of genetic, dietary, and microbial components. Nutrient catabolism from the diet carried out by the microbiota results in the formation of metabolites that impact on the mucosal cells of the intestine, modulating immune responses. Since it has been reported that IBD patients have altered microbiota compared to healthy individuals, we propose as hypothesis that urinary metabolic profiling distinguishes people with IBD from healthy individuals. To study this, we performed a metabolomic analysis of urine samples from healthy individuals and patients with IBD evaluated by gas chromatography (GC) coupled to a mass detector (MS). Bioinformatics analysis of the results using MetaboAnalyst software identified metabolites that characterize both CD and UC and could be used as indicators to improve the diagnosis, monitoring, and treatment of patients with IBD.